Treatment for RSV in Children
The treatment for RSV infection in children is primarily supportive care, as there is no effective antiviral therapy—monoclonal antibodies like palivizumab and nirsevimab are for prevention only, not treatment of active infection. 1, 2
Core Treatment Principles
No Effective Antiviral Treatment
- Controlled studies definitively demonstrate that monoclonal antibodies have no therapeutic benefit once RSV infection is established. 1
- Palivizumab administered intravenously to RSV-infected, intubated infants reduced viral load in the lower respiratory tract but showed no difference in disease severity, duration of hospitalization, oxygen requirements, ICU admission rates, or need for mechanical ventilation compared to placebo. 1
- Ribavirin is the only licensed antiviral for RSV but is not recommended for routine clinical use due to drug toxicity and minimal clinical benefit. 3
Supportive Care Management
Management focuses on ensuring adequate nutrition and respiratory support with minimal interventions. 2
Key supportive measures include:
- Oxygen supplementation for hypoxemia 4, 3
- Feeding support to maintain hydration and nutrition 2, 3
- High-flow nasal cannula appears beneficial in severe cases 4
- Mechanical ventilation when necessary for respiratory failure 3
Hospitalized children should not be subjected to measures with no proven effect—treatment should be focused and evidence-based. 2
Prevention Strategies for High-Risk Infants
Monoclonal Antibody Prophylaxis
Nirsevimab is now preferred over palivizumab due to its long-acting properties. 2, 5
Palivizumab Indications (Historical/Where Nirsevimab Unavailable)
- Infants with chronic lung disease requiring medical therapy within 6 months before RSV season 6
- Infants born ≤32 weeks gestation and younger than 12 months at RSV season start 6
- Infants born 32-35 weeks gestation with 2 or more risk factors (child care attendance, school-aged siblings, environmental air pollutants, congenital airway abnormalities, severe neuromuscular disease) and younger than 6 months at season start 6
- Children ≤24 months with hemodynamically significant congenital heart disease 6
- Five monthly doses maximum during RSV season (November through March in Northern Hemisphere) 6, 1
Nirsevimab Current Recommendations
- Universal prophylaxis for all infants aged 0-3 months during RSV season 2
- Infants under 12 months with increased risk of severe RSV 2
- Certain high-risk children under 24 months 2
- If supply is limited, prioritize children at highest risk 2
Maternal Vaccination
- Maternal vaccination during pregnancy lowers risk of severe RSV in newborns with protective effect equivalent to monoclonal antibodies. 2
- Pre-fusion subunit protein vaccine (Abrysvo) has been licensed for pregnant women following established safety and efficacy trials. 5
- Reduces medically attended RSV-associated lower respiratory tract illness with vaccine efficacy of 54%, severe cases with efficacy of 74%, and hospitalizations with efficacy of 54%. 7
Infection Control Measures
Strict infection-control practices are essential, especially in high-risk units. 1
- Hand hygiene is paramount 6, 1
- Restrict visitors to neonatal ICU during respiratory virus season 1
- Keep high-risk infants away from crowds and situations with uncontrolled exposure to infected individuals 6
- Restrict participation in group child care during RSV season for high-risk infants 6
- Evidence does not support using palivizumab to prevent healthcare-associated RSV spread during outbreaks—primary emphasis should be on proper infection control 1
Critical Pitfalls to Avoid
- Do not use monoclonal antibodies as treatment for active RSV infection—they are prophylactic only 1
- Do not expose high-risk infants to tobacco smoke—this is a controllable risk factor that families must address 6
- Do not administer more than 5 monthly doses of palivizumab within continental United States—this provides >6 months of protective serum concentrations 1
- Do not delay prophylaxis initiation—once an infant qualifies at season start, continue throughout the season regardless of reaching 6 or 12 months of age 6